Home Infusion for Multiple Sclerosis: Ocrevus, Tysabri, and What Patients Should Know

June 11, 2026

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath surrounding nerve fibers, disrupting signal transmission and causing progressive neurological symptoms. For patients with relapsing MS and certain forms of progressive MS, high-efficacy IV biologic therapies have become a cornerstone of disease management.


Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated infusion center visits every six months or four weeks. Pharmko supports MS patients and their neurologists across 22+ states with full clinical coordination and nursing support.


IV Biologic Therapies Used in Multiple Sclerosis


Ocrevus (ocrelizumab)

Ocrevus is an anti-CD20 monoclonal antibody that depletes B cells, a key driver of MS inflammation and neurodegeneration. It is FDA-approved for both relapsing MS and primary progressive MS (PPMS), making it the first therapy approved for PPMS. Ocrevus is administered twice yearly by IV infusion, with the first dose split into two infusions two weeks apart.


Each infusion takes approximately 3.5 hours for subsequent doses (the initial doses take up to 5 hours due to slower administration rates). Vital sign monitoring is required throughout. Pre-medications, methylprednisolone, an antihistamine, and acetaminophen, are given before each infusion to reduce the risk of infusion-related reactions.


Tysabri (natalizumab)

Tysabri is an alpha-4 integrin inhibitor that prevents immune cells from crossing into the central nervous system. It is administered monthly by IV infusion over approximately one hour. Tysabri is highly effective for relapsing MS but carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the JC virus, that requires regular monitoring and patient stratification.


Patients on Tysabri are tested for JC virus antibodies periodically, and their neurologist determines whether the benefit-risk profile supports continued therapy. This monitoring context is an important part of home infusion coordination.


Lemtrada (alemtuzumab)

Lemtrada is administered in two treatment courses, a 5-day course in year one and a 3-day course in year two, typically in a supervised clinical setting due to its intensive monitoring requirements. It is not commonly administered at home, but post-treatment monitoring visits can be coordinated through Pharmko when clinically appropriate.


Who Qualifies for Home Infusion of MS Biologics?


Home infusion for MS therapies is appropriate for patients who have:


  • Completed their initial infusion doses in a supervised clinical or infusion center setting without significant reactions
  • Received pre-infusion medications per protocol and tolerated them without complications
  • Been assessed by their neurologist as stable and suitable for home-based administration
  • A home environment that supports safe IV infusion with nursing oversight


The decision is made in collaboration between the patient and neurologist. Pharmko works directly with neurology practices to manage the clinical handoff from infusion center to home.


What to Expect During a Home MS Infusion


Before the infusion

A Pharmko nurse reviews your current medications, confirms you have no active infections, and administers pre-medications as ordered. Baseline vital signs are taken and documented.


During the infusion

Your nurse remains present for the full infusion, monitors vital signs at scheduled intervals, and responds immediately to any infusion-related reaction. The rate is slowed or the infusion paused if you experience flushing, chest tightness, or other symptoms.


After the infusion

Vital signs are checked before the nurse departs. Your neurologist's office receives a clinical summary. Know which symptoms require an immediate call after an Ocrevus or Tysabri infusion, delayed reactions can occur in the 24 hours following treatment.


Insurance Coverage for MS Infusion Therapy


Ocrevus and Tysabri are covered under the medical benefit by Medicare Part B and most commercial insurance plans. Prior authorization is required and must include documentation of MS diagnosis, relapse history, and prior treatment history. Pharmko manages the authorization process and coordinates with your neurologist's office to compile the necessary clinical documentation.


For patients interested in a broader overview of biologic therapies for autoimmune conditions, our guide on home infusion for autoimmune diseases provides useful context across conditions.


Contact Pharmko to start a referral: 1-877-540-2003


TPN at Home: Who Qualifies, How It Works, and What to Expect
June 11, 2026
Learn how total parenteral nutrition (TPN) at home works — who qualifies, how it's delivered, what daily life looks like, and how Pharmko supports patients from first dose through long-term therapy.
Low Albumin in Dialysis Patients
June 3, 2026
Low albumin is a key marker of malnutrition in dialysis patients. Learn what causes albumin decline, when IDPN is indicated, and how Pharmko supports renal nutrition across 22+ states.
Home Infusion Pump Types
June 2, 2026
Learn about the different types of infusion pumps used in home therapy, ambulatory, electronic, elastomeric, and CADD pumps, and how your pump is matched to your specific treatment.
Home Infusion for Rheumatoid Arthritis
May 30, 2026
Learn how home infusion therapy works for rheumatoid arthritis — including Remicade (infliximab) and other IV biologics, who qualifies for home treatment, and how Pharmko supports ongoing RA care.
Sterile Compounding Safety
May 26, 2026
When a patient or provider chooses a compounding pharmacy to prepare IV medications, they are trusting that the pharmacy operates under rigorous, independently enforced standards. In the United States, those standards are defined by two chapters of the United States Pharmacopeia: USP <797> for sterile compounding and USP <800> for hazardous drug handling. Pharmko operates in full compliance with both chapters. Understanding what these standards require, and what happens when they are not met, helps patients and providers make informed decisions about which pharmacy they trust with their care. What Is USP <797>? USP <797> (Pharmaceutical Compounding, Sterile Preparations) is the national standard that defines the minimum requirements for compounding sterile preparations safely. It covers: Cleanroom environment classification, ISO Class 5 at the point of compounding, ISO Class 7 for the surrounding buffer area, ISO Class 8 for the ante-room Personnel training, gowning, and aseptic technique requirements Sterilization and filtration methods by product type Beyond-use dating (BUD), how long a compounded sterile preparation remains safe to use Environmental and personnel monitoring schedules Quality assurance, documentation, and deviation management USP <797> applies to every pharmacy that prepares IV solutions, injections, eye drops, or other sterile preparations, whether they are a hospital pharmacy, ambulatory infusion center, or specialty pharmacy like Pharmko. The 2023 Revision: What Changed USP <797> was significantly revised in 2023 (effective November 2023). Key changes include: Stricter beyond-use date requirements, compounded sterile preparations must now meet more conservative dating limits unless sterility testing supports extended dating Enhanced environmental monitoring, more frequent air and surface sampling with defined action levels Clearer personnel qualification requirements, competency assessments are now required at defined intervals New category system, preparations are now categorized (Category 1 and Category 2) based on sterility assurance level and BUD Pharmacies that were compliant under the previous version of USP <797> must have updated their procedures and infrastructure to meet the 2023 revision. Pharmko updated our facilities, policies, and documentation systems in alignment with the revised chapter. What Is USP <800>? USP <800> (Pharmaceutical Compounding, Hazardous Drugs) establishes standards for the safe handling of hazardous drugs throughout the pharmacy, from receipt and storage to preparation, dispensing, and waste disposal. Hazardous drugs include certain chemotherapy agents, antiviral medications, hormones, and other drugs that pose risks of carcinogenicity, reproductive toxicity, or organ damage at low exposure levels. USP <800> requires: Negative-pressure ventilated containment primary engineering controls (C-PECs) for hazardous drug compounding Separate, dedicated hazardous drug storage areas Personal protective equipment (PPE) requirements for all staff handling hazardous drugs Closed-system drug transfer devices (CSTDs) for certain preparations Spill kits and exposure management protocols Why These Standards Matter for Patients The consequences of non-compliance are serious. High-profile compounding pharmacy failures, including a 2012 fungal meningitis outbreak linked to contaminated steroid injections that killed 64 patients and injured hundreds, demonstrated what happens when sterile compounding standards are not followed. For patients receiving home IV therapy, USP <797> compliance is not a credential to check once and forget, it reflects the ongoing daily practices of the pharmacy preparing their medications. Patients and providers should verify that any pharmacy preparing their IV solutions is accredited, state-licensed, and actively compliant with current USP standards. How Pharmko Meets These Standards Pharmko's sterile compounding facility is designed, staffed, and operated to meet USP <797> and USP <800> requirements. We are ACHC accredited, state-licensed in 22+ states, and subject to regulatory inspection. Every batch we compound is reviewed by a licensed pharmacist, and our environmental and personnel monitoring data is reviewed on a defined schedule. For a broader overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . For providers interested in our compounding capabilities, see our physician services page or contact our pharmacy team directly. → Contact Pharmko about sterile compounding: 1-877-540-2003
What Is Sterile Compounding and Why Does It Matter for IV Therapy?
May 19, 2026
When a patient needs a medication that is not commercially available in the right dose, formulation, or combination, a sterile compounding pharmacy creates it. Sterile compounding is the process of preparing customized, injectable or infusible medications, IV solutions, eye drops, inhalation solutions, in a controlled, contamination-free environment. Pharmko's sterile compounding services are at the core of what makes specialty pharmacy different from a retail pharmacy. Every IV medication we prepare is custom-compounded, validated, and released by a licensed pharmacist before it reaches a patient. What Makes Compounding 'Sterile'? The word 'sterile' refers to the absence of viable microorganisms, bacteria, fungi, endotoxins, in the final product. This is non-negotiable for any medication injected into or infused through the body. A contaminated IV solution can cause severe bloodstream infections, sepsis, or death. Achieving sterility requires: A controlled cleanroom environment (ISO Class 5 or better at the point of compounding) Positive or negative air pressure depending on the type of medication being prepared Gowning, gloving, and aseptic technique by trained pharmacy staff Validated sterilization methods (filtration, terminal sterilization) appropriate for each formulation Environmental and personnel monitoring to detect contamination risks before they reach patients How Sterile Compounding Differs from Retail Pharmacy A retail pharmacy dispenses commercially manufactured medications in their existing forms — tablets, capsules, pre-made liquids. A sterile compounding pharmacy like Pharmko creates medications that either do not exist commercially, are no longer commercially available, or must be customized for a specific patient. Examples of why sterile compounding is necessary: A patient needs a specific antibiotic concentration not available in commercial vials TPN must be formulated individually based on the patient's weight, labs, and nutritional requirements — no pre-made product covers every case A pediatric patient needs a lower concentration of an IV medication than any commercial product offers IV antibiotics must be prepared in specific volumes and concentrations for OPAT patients based on the prescribed regimen What Is USP <797>? USP <797> is the United States Pharmacopeia chapter that sets the standards for sterile compounding. It defines the environmental requirements, beyond-use dating, testing, personnel training, and quality systems that a pharmacy must maintain to legally compound sterile preparations. Compliance with USP <797> is required by state pharmacy boards and enforced through inspections. Not all compounding pharmacies meet these standards — patients and providers should verify that any pharmacy preparing IV medications is operating in full USP <797> compliance. For a detailed breakdown of what USP <797> and the newer USP <800> standard mean for patient safety, see our guide on sterile compounding safety standards . How Pharmko's Compounding Process Works Pharmko operates a state-of-the-art USP <797> compliant sterile compounding facility. Every product we prepare goes through: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained pharmacy technicians in an ISO Class 5 laminar airflow workbench or biological safety cabinet In-process and final product checks by a licensed pharmacist Sterility testing or filtration validation where required Cold-chain delivery to the patient or dialysis clinic within validated stability windows Why It Matters for Home Infusion Patients Every IV therapy delivered through Pharmko's home infusion services is compounded in our sterile facility. This means patients at home receive the same quality-controlled, pharmacist-verified products they would receive in a hospital — not medications assembled at the bedside or sourced from uncredentialed suppliers. → Contact Pharmko to learn more about our compounding services: 1-877-540-2003
Home Infusion Therapy in Florida
May 19, 2026
Pharmko provides home infusion therapy across Florida, IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, accredited, and available 24/7 statewide.
Home Infusion Therapy in Texas
May 19, 2026
Pharmko provides home infusion therapy across Texas — IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, accredited, and available 24/7 statewide.
 Phosphate Binders for Dialysis Patients
May 12, 2026
Learn how phosphate binders work for dialysis and CKD patients, the different types available, how they fit into a renal care plan, and how Pharmko supports dialysis centers with consistent supply.
 Home Infusion for Autoimmune Diseases
May 7, 2026
Learn how home infusion therapy supports autoimmune disease management,from IVIG for immune deficiencies to biologic infusions for inflammatory conditions. Pharmko serves 22+ states.
Show More